Biopharma’s “patent cliff” isn’t just a legal event—it’s a commercial deadline.
If you’re a commercial market access vendor, a BD leader, or a pharma services provider, the question isn’t whether you can win EU tenders. It’s whether you can win them …

Biopharma talent is moving—fast—and the trail is showing up in the most unglamorous place: patent litigation.
A new wave of biosimilar patent wars isn’t just reshaping product timelines. It’s reshaping careers. If you want to understand where biopharma…

Specialty pharmacy contracts don’t just “happen” after a drug launches. In many cases, they’re won—or lost—before the ink is dry on the patent clock.
That’s the uncomfortable truth biopharma commercial teams and market-access vendors are increasingly f…

The Internet Keeps Asking: “Can This Drug Do That?”—Pharmacology Keeps Sighing.
Every week, someone asks the same question—usually in a comment thread, sometimes in a group chat, often with a screenshot of a headline: “Can this drug treat X?” Or: “Does…

Stop the DIY Drug Patent Search. The FTO Opinion You Skip Can Cost You More Than You Think.
In pharma, “good enough” diligence is rarely good enough.
A recent DrugPatentWatch post highlights a risk that many companies—especially those moving fast—under…

Stop the DIY Patent Search: The FTO Opinion That Could Save You From “Willful” Infringement
In pharma, the most expensive mistake is often the one you don’t realize you made—because you thought you were being careful.
A growing number of companies are …

Pharma procurement teams don’t buy “a drug.” They buy a financial outcome—and most organizations still price that outcome like it’s a line item.
Here’s the uncomfortable truth: the real cost of a drug isn’t the invoice price. It’s the total cost of own…

Pharma doesn’t just invent drugs—it also extends them.
A new analysis from DrugPatentWatch lays out how “patent term extensions” can turn what looks like a narrow legal window into billions in additional revenue. The headline is simple: when exclusivit…

Generic drugmakers don’t “wait their turn.” They litigate their way to it.
In the U.S., the path from patent expiry to pharmacy shelves is rarely a straight line. It’s a chessboard—one where timing, filings, and leverage matter as much as the science…

The real battleground in pharma isn’t the patent—it’s the procurement.
Most companies treat “patent cliff” planning like a legal exercise: file the right reformulation, extend the right exclusivity, protect the right molecule. But in the real world, th…